The US Food and Drug Administration approved a generic once-daily injectable version of the glucagon-like peptide-1 receptor ...

Nearly half of US adults admit they’d take one of the newer, injectable weight loss drugs, but that number falls ...

Individual usage of glucagon like peptide 1 receptor agonists reduced the risk of hospitalization due to alcohol and substance use disorders.

Liraglutide injection is now approved for adult and pediatric patients ages 10 and up, proving another option amid the GLP-1 ...

The approval marks the second for a generic in this class of medications indicated to improve glycemic control in patients ...

The history of weight loss medicines reads like a Greek tragedy. However, the biology behind the new GLP-1 agonists suggests ...

Today, the U.S. Food and Drug Administration approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter, a glucagon-like peptide-1 (GLP-1) ...

The nod, just months after topline results from SURMOUNT-OSA came out, makes it the first drug approved for this indication.

Researchers explore the therapeutic potential and clinical insights of GP1-RAs in the management of metabolic ...

The U.S. Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the ...

Many people with type 2 diabetes can manage their blood sugar levels with lifestyle changes, including exercise and nutrition ...